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Abstract
Background: A large prospective study in patients with type 2 diabetes (T2D), the German D2C cohort, is
presently being enumerated to investigate risk factors of incident cancer in diabetic patients.
Study setting: A disease management program was offered, on a voluntary basis, to all T2D patients who were
members of a statutory health insurance fund in Germany. This first feasibility report uses data from 26.742 T2D
patients, who were 40 to 79 years old, resided in the Muenster District, and who were enrolled between June 2003
and July 2008. Cancer cases were identified through the regional Cancer Registry.
Methods: Invasive cancer cases were identified using probabilistic record linkage procedures and pseudonymised
personal identifiers. Censoring date was December 31, 2008. We included only first cancers, leaving 12.650 male
and 14.092 female T2D with a total of 88.778 person-years (py). We computed standardised incidence ratios (SIR)
for external comparisons and we employed Cox regression models and hazard ratios (HR) within the cohort.
Results: We identified 759 first cancers among male T2D patients (18.7 per 1,000 py) and 605 among females (12.7
per 1,000 py). The risk of any incident cancer in T2D was raised (SIR = 1.14; 95% confidence interval [1.10 - 1.21]), in
particular for cancer of the liver (SIR = 1.94 [1.15 - 2.94]) and pancreas (SIR = 1.45 [1.07-1.92]). SIRs decreased
markedly with time after T2D diagnosis. In Cox models, adjusting for diabetes duration, body mass index and sex,
insulin therapy was related to higher cancer risk (HR = 1.25 [1.17 - 1.33]). No effect was seen for metformin.
Discussion: Our study demonstrates feasibility of record linkage between DMP and cancer registries. These first
cohort results confirm previous reports. It is envisaged to enhance this cohort by inclusion of further regions of the
state, expansion of the follow-up times, and collection of a more detailed medication history.
Background
Evidence from epidemiological observation studies sug-
gests that pathophysiological conditions involving hyper-
insulinaemia, such as obesity or sedentary behavior, are
risk factors for the development of malignant neoplasias
[1-4]. Likewise, for type 2 diabetes (T2D), a disorder in
which obesity is a major risk factor and insulin resis-
tance an inherent characteristic, recent findings have
been accumulated that link this disease and its treat-
ment with the risk of cancer [2,4-11]. In June 2010, an
expert consensus report on Diabetes and Cancer was
published that assesses the scientific evidence regarding
this issue. This report identified numerous unanswered
questions in four broad areas. First, more research is
required into the specific, especially the less common,
cancer types and the impact on cancer prognosis and
mortality in T2D including the role of diabetes duration
and multidrug therapy. Second, the complex interplay of
life style and genetic factors, and their relation over
time, needs to be better elucidated. Third, diabetes and
cancer may share common predisposing factors, such as
hyperglycaemia, hyperinsulinaemia, and inflammation,
without being causally related - resulting in the question
whether metabolic insulin resistance is accompanied by
growth promoting effects of hyperinsulinemia. Last, how
can one assess the independent associations between a
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any medium, provided the original work is properly cited.specific medication and cancer risk, relative to no medi-
cation, when the progressive nature of T2D requires
adaptation of therapy over time? The expert panel con-
cluded that randomised controlled clinical trials will be
unlikely to fully address all these questions, and that
multiple well conducted and appropriately designed pro-
spective studies are needed [1,5].
W er e p o r th e r et h eb a s e l i n er e s u l t sf r o mal a r g e
cohort study, the ‘Diabetes II-to-Cancer’ (D2C) cohort,
that aims to provide detailed information on the occur-
rence of incident cancer of various types. It involves
T2D patients from a state-wide disease management
program who were linked with records from a popula-
tion-based state cancer registry.
Methods
Disease Management Program Diabetes Type 2
The German Statutory Health Insurance (SHI) system
consists of more than one hundred sickness funds, which
are non-profit insurance companies covering inpatient
and ambulatory care as well as pharmaceuticals, and
insure about 90 percent of the nation’sp o p u l a t i o n .G e r -
many is the only country that has implemented a nation-
wide primary care-based and physician-sustained disease
management program, currently accessible to around 90
percent of the population [12]. Disease management pro-
grams (DMP) were introduced in 2003 for patients pre-
viously diagnosed with type 2 diabetes. Physician’sa n d
patient’s participation in the program is voluntary. Pri-
mary care physicians enrol patients, and they educate
and advise those patients with respect to the manage-
ment of their disease and use of the health care system.
The program includes regular physician-patient consulta-
tions at three-month intervals, including a diabetes-speci-
fic physical examination, lab tests, patient education,
discussion of patient-specific treatment goals, specialist
referral if required, documentation of all medical findings
in a standardised documentation routine, and treatment
according to evidence-based guidelines.
Epidemiological Cancer Registry NRW
The Cancer Registry of the state of North-Rhine-West-
phalia (EKR NRW) collects, links, stores and analyses
data about state-wide incident cancer disease. It pro-
vides a database for reports and research about the fre-
quency, distribution, and occurrence of cancer diseases
in the population of NRW including also survival ana-
lyses. It requires, and accepts, with exception only elec-
tronic notifications of incident cancer cases. The
notification of the first diagnosis of a cancer case by the
treating and/or diagnosing physicians is required by law
and mandatory. Mortality and survival of cancer patients
is assessed on an annual basis by linking cancer cases in
the EKR NRW with electronic reports on all deceased
individuals in NRW obtained from population registra-
tion offices.
For reasons of data confidentiality, the law stipulates
that personal identifiers of each cancer case may not be
stored as plain text in the registry but only in an encrypted
manner. Therefore, encryption procedures were devised
for the encryption of each notification of a cancer case as
well as for death certificates. Specifically, the personal
identifying variables (i.e., family name, first names, birth
name, street and house number, and day of birth) are sub-
mitted to an initial (one-way) encryption in the notifying
office (i.e., hospital, physician’s office or pathologist) before
the data are released. These initially encrypted data are
transmitted over a secure data line to a dedicated server
which is located within the special security network of the
Cooperation of SHI-based physicians. Here, a second
(symmetrical) encryption procedure is completed before
the data are forwarded to the EKR NRW. All medical and
epidemiological data and part of the personal identifiers
(sex, month and year of birth, postal code and place of
residence, nationality) remain in plain text and are sent
directly via a separate safe network to the EKR NRW. The
two parts of each notification are linked again in the regis-
try before entering the internal processing (coding, linkage
and best-of-tumour generation). The procedure is labelled
‘pseudonymisation’ and generates a unique string of char-
acters which allows the unequivocal assignment of specific
pseudonyms to the original name [13]. These pseudonyms
are the basis for all subsequent record linkage procedures
within the EKR NRW. All record linkage procedures are
semi-automatic and entirely probabilistic. The estimated
completeness of cancer registration in the EKR NRW is
over 90% [14].
Record linkage between DMP data base and EKR NRW
In addition to administrative data, including day of
DMP enrolment, the standardised documentation com-
prised information on anthropometry and physical
examination including laboratory tests, type of diabetes
medication, duration, symptoms and complications of
diabetes, concurrent morbidity, and medical history.
Most data of the DMP patients are stored in a central
data bank. After details on sex and place of residence,
which were kept separately in the SHI files, were linked
to the central data bank by individual insurance num-
bers, records could be submitted to the pseudonymisa-
tion process required for the stochastic record linkage
with the EKR NRW [13].
Feasibility study
We report here the results of the first feasibility study
that was conducted to enumerate the D2C cohort and
establish the procedures of record linkage. We obtained
the data of 125,211 DMP patients from one of the
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sively patients from Westphalia-Lippe, the Northwestern
region of NRW. The date of patients’ enrolment ranged
from June 2003 to the end of July 2008. The feasibility
tests were performed on a subpopulation of 31,203
DMP patients residing in the Regierungsbezirk (Admin-
istrative District) Münster, because cancer registration
in this region was over 95% complete and it was already
in full operation when the DMP started in 2003. Cancer
registration for the rest of Westphalia-Lippe started in
mid 2005 such that other regions reached comparable
levels of completeness only from 2007 onwards. We
further defined an age range from 40 to 79 years, such
that ultimately 27,450 T2D patients were eligible for a
record linkage with the cancer registry.
The record linkage was run at the end of November
2009. All cohort observation data were censored at the
end of 2008 to account for reporting lags. Thus, the
time under risk for each individual cohort patient lasted
either from day of enrolment until December 31, 2008,
or - in the case of cancer occurrence - until the day of
cancer diagnosis. There were 27,843 records produced
as a result of the linkage procedure (Figure 1). Only
cases of a first cancer entered the analysis, multiple can-
cers were ignored. Diabetics for whom a diagnosis of
cancer had been recorded in the EKR NRW before the
day of DMP enrolment (prevalent cancers) were
excluded; likewise, cancer cases detected exclusively by
death certificate (DCO cases) were also excluded. Ulti-
mately, 26,742 patients were available for study analyses.
Figure 1 provides a flow chart depicting the selection
process of our study participants.
Statistical Analyses
Cancer cases were counted as incident when a first diag-
nosis of cancer in the EKR NRW was linked to a DMP
patient, and the diagnosis occurred between program
enrolment and December 31, 2008. Person-years were
used to calculate the time at risk for each individual in
the cohort, either as time to incident cancer or time to
censoring. In this feasibility study, we had no access (yet)
to information on whether a cohort member had died of
cancer or any other cause, or had moved out of the area.
For external comparisons, we calculated standardised
incidence ratios (SIR) to compare the observed numbers
of all cancers, and of specific cancer types, with the
expected numbers of cancer cases [15]. The latter were
derived from the respective annual cancer incidence
rates observed during the observation period in the
source population by the EKR NRW. As source popula-
tion we defined the general population of Regierungsbe-
zirk Münster in the age range 40 to 79 years.
Computations were performed using the program pro-
posed by Wood et al. [16] applying five year age groups,
combining person-years accumulated with the age-
group specific cancer incidence rates in the general
population, which was averaged over the calendar period
2003-2007. We computed confidence intervals to reflect
the precision of the SIR estimates and selected 99% con-
fidence levels to account for the multiple statistical tests
performed on the various cancer entities.
For within-cohort comparisons, we used Cox propor-
tional hazard models to estimate hazard ratios (HR),
employing age as the underlying time-scale and age at
enrolment as delayed entry point, while adjusting for sex,
BMI, diabetes duration as a time-dependent variable, and
medication at study entry. The Cox PH models were spe-
cified a priori so that 95%-confidence intervals were con-
sidered appropriate for their presentation. All analyses
were performed with the statistical software SAS 9.2.
Results
Baseline characteristics of study participants
The cohort subsample selected for the feasibility assess-
ment consisted of 12 650 men and 14 092 women with
an average age of about 63 years in men and 65 years in
women. Expectedly for this group, the body mass index
was high and about one in five men and one in ten
women were active smokers. The median time under
observation was approximately 3.5 years. One in four
patients received no anti-diabetic medication at the time
of enrolment in to the DMP (Table 1).
Crude cancer incidence rates
We observed 1364 cases of incident cancer during a
total follow-up time of 88 773 person-years. The crude
cancer incidence rate was higher in men (18.4 per 1000
Figure 1 Selection of study participants for this study.
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and rates for specific cancers are given in Table 2.
External comparisons with general population
The standardised incidence ratios (SIR) revealed that the
rate of cancer occurrence was higher in this cohort of
diabetics than in the general population as reflected by
an SIR = 1.14 (99% confidence interval [1.04-1.21];
Table 3). The SIR was specifically raised for cancers of
the liver (SIR = 1.94) and for pancreas cancer (SIR =
1.45). Conversely, the risk of prostate cancer was clearly
lowered among diabetics (SIR = 0.65). Incident cancers
of the breast, colorectum and lung were not raised.
Results were largely consistent for men and women.
With regard to cofactors, age did not modify the risk
of cancer among diabetics while body mass index
seemed to have a very moderately increasing impact
(Table 4). Of note, however, the duration of diabetes
w a ss t r o n g l ya n di n v e r s e l ya s s o c i a t e dw i t ht h eo c c u r -
rence of any invasive cancer: this risk was markedly
higher within the first year after diabetes had been
diagnosed.
Internal comparisons within cohort of diabetics
We analysed further how patient characteristics influ-
enced the risk of cancer within this cohort of diabetics.
The risk of cancer was lower among diabetic women.
Obesity seemed inversely related to cancer risk among
diabetics; similarly, diabetes duration was also inversely
associated with occurrence of any cancer. Of the anti-
diabetic medication taken by T2D patients, only insulin,
either alone or in combination with metformin, seemed
to raise the cancer risk significantly (HR = 1.25, 95%
confidence interval [1.17 - 1.33]; Table 5).
Discussion
Our study had two aspects: one was to test the feasibil-
ity of a pseudonymised procedure for the linkage of
records from different data collection systems (DMP
T2D and EKR NRW), and the second was to explore
the incidence of cancer in this cohort over a fairly short
time of observation. The specific record linkage proce-
dures had been positively evaluated before comparing
pseudonymised with plain text personal identifiers
which had been obtained from standardised and struc-
tured cancer case notifications in the EKR NRW. Our
study shows that other sets of data, collected for pur-
poses other than cancer registration, can also be effec-
tively linked by using these procedures. Specific
Table 1 Baseline description of the D2C cohort
Men Women
N 12 650 47,3% 14 092 52,7%
Median follow-up time (years) 3.54 [0.3 - 5.8] 3.79 [0.2 - 5.8]
Mean Age (years) 62.6 [40-79] 65.2 [40-79]
Median BMI (kg/m
2) 29.7 [16.3 - 44.9] 31.0 [16.2 - 44.9]
Current smokers 2934 23.2% 1659 11.8%
Year of enrolment in DMP
2003/2004 5 845 46.2% 6 838 48.5%
2005/2006 3 148 24.9% 3 407 24.2%
2007/2008 3 657 28.9% 3 847 27.3%
Anti-diabetic medication
No medication 3 041 24.0% 3 465 24.6%
Metformin only 4 580 36.2% 5 064 35.9%
Any other oral antidiabetic drug 1 782 14.1% 1 868 13.3%
Human insulin (alone or with metformin) 2 558 20.2% 3 018 21.4%
Insulin Analogues (alone or with insulin and/or metformin) 690 5.5% 677 4.8%
Table 2 Numbers of first invasive cancers and crude
cancer incidence rates in the T2D cohort
Cancer type (ICD-10) Men Women
N = 12.650;
41.170 py
N = 14.092;
47.603 py
Any cancer (excluding C 44*) 759 (18.4 per
1 000 py)
605 (12.7 per
1 000 py)
Liver (C 22) 23 (0.6 per
1 000 py)
10 (0.2 per
1 000 py)
Pancreas (C 25) 22 (0.5 per
1 000 py)
27 (0.7 per
1 000 py)
Breast (C 50) 2 (0.05 per
1 000 py)
129 (2.7 per
1 000 py)
Prostate (C 61) 132 (3.2 per
1 000 py)
-
Colorectal (C18 - C21) 107 (2.6 per
1 000 py)
88 (1.8 per
1 000 py)
Lung (C34) 121 (2.9 per
1 000 py)
42 (0.9 per
1 000 py)
*C44 (Other malignant neoplasms of skin)
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be described somewhere else (in preparation). In gen-
eral, the procedures worked smoothly and efficiently.
Lending support to the validity and credibility of our
study, these descriptive and preliminary results with
regard to cancer incidence among T2D patients appear
to essentially confirm previous reports. Thus, the inci-
dence rate for any type of cancer was found to be raised
among diabetics, when compared with the source popu-
lation, and the size of the elevation was similar to risk
ratios reported in recent meta-analyses and the 2010
consensus report [1,4,5,17]. Similarly, the elevations of
risk for cancers of the liver and pancreas, and the
decreased risk for prostate cancer have also been consis-
tently observed in T2D before [4,17]. We noted, how-
ever, that the SIR was particularly high in the first year
after diabetes was diagnosed. This may be attributable
on one hand to a detection bias which arises when
freshly diagnosed diabetics increase the frequency of
their contacts with the health system or when they are
initially submitted to more intensified medical examina-
tions: In such a situation, prevalent cancers are more
likely to be detected. On the other hand, reverse causal-
ity, that is, cancers compromising glucose-metabolism,
may offer another plausible explanation of such findings.
Of note, this temporal pattern is rather common and
has been discussed recently [2,7,18].
Investigating the factors that impact on cancer occur-
rence within the cohort of diabetic patients, we found -
apart from diabetes duration which had the strongest
inverse influence - that insulin therapy, either as a mono-
therapy or in combination with metformin, increased the
cancer risk by about 25%. This finding is in line with pre-
vious reports [4,6,7,11,18]. We were unable to identify
raised cancer risk among cohort members who took
insulin analogues, either alone or in combination. These
drugs, specifically the long acting modality glargine in
higher dosages, have been recently suspected of being
related to raised cancer risks [2,6,7,11,19]. Unfortunately,
the number of T2D patients taking these medications
was low, the distinction between long and fast acting ana-
logues was presently not possible, nor did we - as yet -
have data on drug dosages. Furthermore, and in contrast
to several recent reports [1,2,5], we could presently not
identify a significant inverse association between metfor-
min use and cancer incidence.
Our study has several limitations. The follow-up period
was rather short for the effects of therapy and cancer ther-
apy to fully develop missing cases with later onset. Like-
wise, taking into account the reporting lag inherent in any
system of cancer registration, population-based complete-
ness of notification can be expected about 18 months after
cancer diagnosis; therefore, a certain degree of underesti-
mation of cancer occurrence in this cohort is likely.
Another bias has probably arisen from the, as yet, unavail-
ability of data on the mobility and mortality of this cohort.
T2D patients are likely to have a higher rate of competing
risks and mortality, e.g. due to cardiovascular diseases,
Table 3 Standardised incidence ratios (SIR) for invasive cancers in the D2C cohort
Cancer type (ICD-10) SIR
Men 99% CI Women 99% CI All 99% CI
Any cancer (excluding C 44*) 1.11 [1.01-1.21] 1.18 [1.07-1.31] 1.14 [1.04-1.21]
Liver (C 22) 1.88 [1.02-3.15] 2.08 [0.78-4.46] 1.94 [1.18-2.99]
Pancreas (C 25) 1.27 [0.68-2.15] 1.63 [0.93-2.63] 1.45 [0.97-2-06]
Breast (C 50) - - 0.86 [0.68-1.07] - -
Prostate (C 61) 0.65 [0.52-0.82] - - - -
Colorectal (C18 - C21) 1.00 [0.77-1.23] 0,97 [0.73-1.28] 0.99 [0.81-1.19]
Lung (C34) 1.04 [0.81-1.31] 1.06 [0.69-1.56] 1.05 [0.85-1.27]
*C44 (Other malignant neoplasms of skin)
Table 4 Standardised incidence ratios (SIR) for all
invasive cancers, by age, BMI and diabetes duration
Variable SIR 99% CI
Age
< 60 years 1.14 [0.94-1.38]
≥ 60 years 1.14 [1.06-1.23]
T2D duration at study entry
< 1 year 1.27 [1.08-1.47]
1 - 3 years 1.13 [0.94-1.34]
> 3 years 1.10 [1.00-1.21]
Table 5 Patient characteristics with impact on total
cancer incidence
Variable HR 95%-CI
Female sex 0.69 [0.65-0.72]
BMI (≥ 30 kg/m
2) 0.90 [0.86-0.95]
Diabetes duration more than 2 years 0.79 [0.73-0.86]
Metformin (only) 0.95 [0.90-1.01]
Insulin (including combination
with metformin)
1.25 [1.17-1.33]
Analogues (including combination
with insulin/metformin)
0.89 [0.79-1.01]
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in diabetics, and it will probably also tend to lower the
relative risk estimates within the cohort. On the other
hand, less seriously ill diabetics may have moved out of
the catchment area of the register and were thus lost to
follow-up; this might have resulted in spuriously increased
hazard ratios. However, the migration rates in this age
group in NRW are generally low and we do not perceive
this mobility to be largely differential; therefore, the effect
on SIR and HR is expected to be small. In summary, the
directions of these potential biases tend mostly to reduce
the observed ratios, and thus our estimates are probably
presumed to conservative rather than overemphasizing.
The D2C cohort will be continued. The number of
patients will be increased by patients residing in other
areas of Westphalia-Lippe as cancer registration became
complete in these areas from 2007 onwards. This will be
complemented by repeating follow-ups annually to
increase the total person-time. Finally, we are presently
attempting to develop a system that will enhance the
availability of data on drug use incorporating type,
dosage and duration for each individual cohort member.
In addition, means are being explored to implement a
pseudonymised record linkage of death records, routi-
nely provided to the EKR NRW, with the DMP cohort
for the assessment of T2D patients’ mortality.
Conclusions
Our study demonstrates feasibility of record linkage
between DMP and cancer registries. The first cohort
results confirm previous reports on the association of
T2D with cancer and the role of insulin therapy. It is
envisaged to enhance the informativeness of this cohort
by inclusion of further regions of the state, expansion of
the follow-up times, and collection of a more detailed
medication history.
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